The Double Marker Test is a prenatal screening test conducted in the first trimester of pregnancy to assess the risk of chromosomal abnormalities in the fetus. It primarily helps in detecting conditions such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13) by analyzing two key biomarkers in the mother's blood: free Beta-hCG (Human Chorionic Gonadotropin) and PAPP-A (Pregnancy-Associated Plasma Protein-A).

Doctors typically recommend the Double Marker Test between the 9th and 13th weeks of pregnancy, especially for women over 35 years of age or those with a family history of genetic disorders. It is usually performed alongside an NT scan (Nuchal Translucency scan) for a more comprehensive risk evaluation. Since it is a non-invasive blood test, it poses no risk to the mother or baby.

It is important to note that this is a screening test, not a diagnostic one. A high-risk result does not confirm a genetic condition but suggests the need for further confirmatory tests like Chorionic Villus Sampling (CVS) or Amniocentesis. Early detection through this test allows for better pregnancy management and informed decision-making.